New Prenatal Genetic Screens Pose Underappreciated Ethical Dilemmas
By Daniel Navon,
Scientific American
| 05. 05. 2022
Imagine you are an expectant parent. Just a couple of months into your pregnancy, you opt for an easy genetic screen. A result comes back: the fetus is likely missing a chunk of DNA at site 11.2 on the long arm of the 22nd chromosome—a variant associated with serious medical and developmental issues.
You go online and learn that at least 1 in 4,000 people have this “22q11.2” microdeletion, but the true figure may be much higher. You read about 22q11.2 deletion syndrome’s 180-plus symptoms, including heart malformations, hypocalcemia, intellectual disability, autism and schizophrenia. You discover the bewildering treatment guidelines, the specialist clinics scattered throughout the country, and the vibrant patient advocacy movement spearheaded by the International 22q11.2 Foundation.
Yet the same pathogenic variant—a genetic change or “mutation” known to cause disease—has been found in people with much milder symptoms, and some who barely seem affected at all. No one can give you solid risk factors because our knowledge of 22q11.2 deletion syndrome (also known as DiGeorge syndrome) is riddled with “ascertainment bias”: only people with telltale problems are... see more
Related Articles
A Eugenics Society poster (1930s) from the
Wellcome Library Eugenics Society Archive via Wikimedia
On a Saturday afternoon in May, Payton S. Gendron shot 13 people, almost all Black, at a supermarket in Buffalo, killing 10. This was hardly an isolated incident: It was one of over 200 mass shootings so far this year. Only 10 days later, at least 21 people died in a school shooting at Uvalde, Texas. That killer was apparently a lonely, bullied 18-year-old with a...
By Michael Eisenstein , Nature | 05.09.2022
Two companies, Beam Therapeutics and Verve Therapeutics, are leading the charge of base editing therapies to the clinic. Last November, Beam got the green light from the US Food and Drug Administration (FDA) for its upcoming BEACON-101 trial that will...
By Kevin Davies, Genetic Engineering and Biotechnology News | 05.18.2022
WASHINGTON, DC — In his current role as President Biden’s acting scientific advisor, Francis Collins, MD, PhD, is dealing with a wide range of issues from semiconductor shortages to wildfires. “But my heart is in what you are all doing...
By Daniel Navon, Scientific American | 05.05.2022
Imagine you are an expectant parent. Just a couple of months into your pregnancy, you opt for an easy genetic screen. A result comes back: the fetus is likely missing a chunk of DNA at site 11.2 on the long...